ASLAN Pharmaceuticals EBIT

ASLAN Pharmaceuticals (ASLN) currently reports a EBIT of $-35M as of March 2024. That compares with $-54M in the prior-year period — up 35.4% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore ASLAN Pharmaceuticals's EBIT history and peer comparisons.

ASLAN Pharmaceuticals's EBIT increased from $-54M to $-35M — a 35.4% year-over-year increase (period ending March 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

ASLAN Pharmaceuticals's EBIT of $-35M is lower than the Healthcare sector average of $22B. That is roughly 100.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

ASLAN Pharmaceuticals reported $-35M in EBIT as of March 2024. That compares with $-54M in the prior-year period — up 35.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-35M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for ASLAN Pharmaceuticals, and consider following ASLN for alerts when major investors trade the stock.